JIVI

Bayer Inc🇨🇦 Health Canada

Approval Id: 39ce18c9a7b1f07f
Drug Approval Canada Name: JIVI
Product Name: JIVI
Status: Marketed
Status Date: 2020-04-08
Original Market Date: 2020-04-08
Din: 02481766
Drug Class: Human
Dosage Form: Powder For Solution
Route Of Administration: Intravenous
Schedule: Schedule D
Ahfs: 20:00.00
Atc Original: B02BD02 COAGULATION FACTOR VIII
Atc Name: b 02 bd 02
Aig Number: 0160750002
Company Name: Bayer Inc
Company Address: 2920 Matheson Blvd East, Mississauga, Ontario, Canada, L4W 5R6

ANTIHEMOPHILIC FACTOR (RECOMBINANT, B-DOMAIN DELETED, PEGYLATED)

500 UNIT / VIAL

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

39ce18c9a7b1f07f

Type

Standard